Kyle Weant to Cost-Benefit Analysis
This is a "connection" page, showing publications Kyle Weant has written about Cost-Benefit Analysis.
Connection Strength
0.230
-
Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom at an academic medical center. Pharmacotherapy. 2012 May; 32(5):433-40.
Score: 0.085
-
Evidence-based, multidisciplinary approach to the development of a crotalidae polyvalent antivenin (CroFab) protocol at a university hospital. Ann Pharmacother. 2010 Mar; 44(3):447-55.
Score: 0.073
-
Cost effectiveness of a clinical pharmacist on a neurosurgical team. Neurosurgery. 2009 Nov; 65(5):946-50; discussion 950-1.
Score: 0.072